Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafasitamab - Incyte Corporation

Next Previous
X
Search
Drug Profile

Tafasitamab - Incyte Corporation

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; ICP-B04; INCMOR0208; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Incyte Corporation; InnoCare Pharma; Knight Therapeutics; MorphoSys; Pfizer; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Phase III Follicular lymphoma; Marginal zone B-cell lymphoma
  • Phase II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Aug 2024 Incyte announces intention to file a sBLA for tafasitamab for Follicular lymphoma by the end of the year
  • 15 Aug 2024 Efficacy data from the phase III inMIND trial in Follicular Lymphoma released by Incyte
  • 21 Jun 2024 MorphoSys completes a phase-II/III trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Portugal, Australia, Turkey, Romania, New Zealand, Poland, Italy, Germany, United Kingdom, Singapore, South Korea, Czech Republic, Canada, Israel, Taiwan, Serbia, Croatia, Spain, Finland, Austria and Hungary, France(IV) (NCT02763319)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top